Help Us Fight
Coronavirus
You can support our groundbreaking COVID-19
research by making a contribution today.
Scientists analyzed about 1,200 proteins from the longitudinal blood samples of 79 participants of a commercial wellness program, including samples collected pre-diagnosis from 10 cancer patients. For three patients who went on to be diagnosed with three distinct types of metastatic cancer, the research team found specific proteins that were significant outliers when compared to other program participants.
One protein — CEACAM5 — was a persistent outlier for every metastatic diagnosis (breast, lung and pancreatic cancers), and appeared as early as 26.5 months before diagnosis. Importantly, CEACAM5 was not an outlier for any non-metastatic cancer diagnosis or control patient.
Two proteins — CALCA and DLK1 — were specific to metastatic pancreatic cancer, and were outliers at least 16.5 months before diagnosis. Another protein — ERBB2 — was specific to metastatic breast cancer, and spiked significantly between 10 and four months before diagnosis.
“These results support the value of deep phenotyping seemingly healthy individuals to prospectively infer disease transitions,” said Dr. Andrew Magis, who led the study. The findings were published in the journal Scientific Reports.
Andrew Magis, PhD
A central premise of P4 medicine (predictive, preventive, personalized and participatory) is identifying the early markers that signal transitions from health to disease. For cancer patients, identifying cancer before it metastasizes enables localized treatment options to remove the primary cancer, which improves survival and reduces the likelihood of recurrence.
Typically, studies seeking to identify cancer biomarkers compare samples of diagnosed cancer patients with non-cancer controls. However, there is greater learning potential when analyzing pre-diagnosis samples from healthy individuals who are later diagnosed with cancer. While these opportunities are rare, they can yield insights into early signals and mechanisms of disease transitions.
“While follow-up studies examining more study participants are clearly needed to validate the clinical utility of these observations, CEACAM5 represents a promising candidate for much earlier warning of metastasis than was previously known,” said Dr. Nathan Price, ISB professor and associate director and co-leader of the Hood-Price Lab.
This research builds on other important ISB findings, notably that genetic risk for disease is often reflected in our blood; molecular and physiological information can determine an individual’s biological age, which can serve as a more effective and reliable predictor of overall health than chronological age; that the alpha diversity of an individual’s gut microbiome can be accurately predicted by examining metabolites in the blood; and that combining personal, dense, dynamic data (PD3) clouds with tailored behavioral coaching can optimize wellness and the PD3 clouds can identify early transitions into disease states and facilitate the reversal of some disease states back to wellness.
Category: Press Release, Publications
Tags:Andrew Magis, biomarkers, cancer, cancer biomarkers, cancer research, deep phenotyping, disease transitions, early warning signs, Health Data Science Lab, Hood-Price Lab, metastatic cancer, Nathan Price, pre-diagnosis, proteins, Proteomics, publication, Scientific Reports
Christopher Lausted and Dr. Danielle Vermaak were featured guests of an ISB Research Roundtable presentation. The husband-and-wife team detailed the planning and rollout of a DNA sequencing curriculum project that was tested in Vermaak’s Lincoln High School science classroom in Seattle.
A just-published study provides new information about which hospitalized COVID-19 patients are most likely to need mechanical ventilation or to die. The ISB-led work shows that vital signs and lab results at the time of hospital admission are the most accurate predictors of disease severity, more so than comorbidities and demographics.
Researchers have identified several factors that can be measured at the initial point of COVID-19 diagnosis that anticipate if a patient is likely to develop long COVID. They also found that mild cases of COVID-19, not just severe cases, are associated with long COVID. Their findings were published by the journal Cell.
You can support our groundbreaking COVID-19
research by making a contribution today.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.